Scancell Holdings Plc Hardman Research: SCIB development update
March 13 2017 - 2:15AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
13 March 2017
Hardman Research: SCIB development update
SCIB development update: Scancell is a clinical stage
pharmaceutical company developing two distinct flexible cancer
immunotherapy platforms, each with broad applications. ImmunoBody
is a DNA vaccine which stimulates high avidity anti-tumour T-cells
for use as a monotherapy or in combination with checkpoint
inhibitors. Moditope targets modified antigens and stimulates
powerful anti-tumour T-cell responses for use in advanced and
hard-to-treat cancers. Both platforms are targeting multi-billion
dollar markets. 2017 will concentrate on raising the necessary
funds to enable the commencement of a Phase II SCIB1 trial in
combination with a checkpoint inhibitor.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/sclp---interim-scib-update---13th-march-2017.pdf
To contact us: Contacts:
Hardman & Co Dr Martin Hall
11/12 Tokenhouse mh@hardmanandco.com
Yard Dr Dorothea Hill
London dmh@hardmanandco.com
EC2R 7AS Dr Gregoire Pave
gp@hardmanabdco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFSDVLIILID
(END) Dow Jones Newswires
March 13, 2017 03:15 ET (07:15 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024